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Prostaglandin E2 (PGE2) is a key mediator involved in several inflammatory conditions. In this study, we investigated the expression and
regulation of the terminal PGE2 synthesizing enzyme prostaglandin E synthases (mPGES-1, mPGES-2 and cPGES) in gingival fibroblasts
stimulated with pro-inflammatory cytokines. We used siRNA knockdown of mPGES-1 to elucidate the impact of mPGES-1 inhibition on mPGES-
2 and cPGES expression, as well as on PGE2 production. The cytokines TNFα and IL-1β increased protein expression and activity of mPGES-1,
accompanied by increased COX-2 expression and PGE2 production. The isoenzymes mPGES-2 and cPGES, constitutively expressed at mRNA
and protein levels, were unaffected by the pro-inflammatory cytokines. We show for the first time that treatment with mPGES-1 siRNA down-
regulated the cytokine-induced mPGES-1 protein expression and activity. Interestingly, mPGES-1 siRNA did not affect the cytokine-stimulated
PGE2 production, whereas PGF2α levels were enhanced. Neither mPGES-2 nor cPGES expression was affected by siRNA silencing of mPGES-1.
Dexamethasone and MK-886 both inhibited the cytokine-induced mPGES-1 expression while mPGES-2 and cPGES expression remained
unaffected. In conclusion, mPGES-1 siRNA down-regulates mPGES-1 expression, and neither mPGES-2 nor cPGES substituted for mPGES-1 in
a knockdown setting in gingival fibroblasts. Moreover, mPGES-1 siRNA did not affect PGE2 levels, whereas PGF2α increased, suggesting a
compensatory pathway of PGE2 synthesis when mPGES-1 is knocked down.
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Prostaglandins, especially prostaglandin E2 (PGE2), are
involved in several inflammatory conditions including rheuma-
toid arthritis [1–3] and atherosclerosis [4,5] as well as peri-
odontitis [6,7]. The biosynthesis of PGE2 from arachidonic acid
requires a sequence of enzyme systems, including the cyclo-
oxygenases (COX-1 and COX-2), converting arachidonic acid
(AA) to prostaglandin H2 (PGH2), and the terminal prostaglan-
din E synthase (PGE synthase), converting PGH2 to PGE2 [8–
12]. PGE2 can then be further metabolized to prostaglandin F2α
(PGF2α) by the enzyme PGE 9-ketoreductase [13,14]. It is well
known that the isoenzyme COX-1 is constitutively expressed⁎ Corresponding author. Tel.: +46 8 524 881 92; fax: +46 8 746 79 15.
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doi:10.1016/j.bbamcr.2007.07.008whereas COX-2 is induced by inflammatory stimuli such as
tumor necrosis factor α (TNFα) and interleukin-1β (IL-1β)
[15,16]. Regarding the downstream enzyme PGE synthase,
three isoforms have currently been characterized: two micro-
somal PGE synthases (mPGES-1 and mPGES-2) and one
cytosolic PGE synthase (cPGES) [11,17–19].
The mPGES-1 isoenzyme has been reported to be induced by
pro-inflammatory cytokines in various cell types, including
cultured gastric fibroblasts, synovial fibroblasts, cardiac fibro-
blasts and gastric cancer cell lines, as well as in gingival fibro-
blasts [19–24]. It has also been shown that mPGES-1 and COX-
2 display functional coupling through coordinate induction upon
stimulation with lipopolysaccharide (LPS) [25]. However, the
absoluteness of this coupling has been questioned, and a lack of
exclusive coordination between these two enzymes has been
reported [26,27]. For example, it was recently shown that
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kinase C or tyrosine kinase signal pathways, suggesting distinct
regulatory mechanisms for mPGES-1 and COX-2 [28].
Since mPGES-1 is important in the regulation of PGE2
synthesis, inhibition of mPGES-1 has been attempted through
several different approaches. Antisense oligonucleotides used to
inhibit mPGES-1 protein expression have been demonstrated to
decrease cytokine-induced PGE2 production in A549 cells,
HCA7 cells and rat microglial cells [29–32]. Moreover, the
indole FLAP (five lipoxygenase activating protein) inhibitor
MK-886, reported to decrease mPGES-1 activity, has also been
shown to decrease PGE2 production in chondrocytes and gastric
fibroblasts [20,33–35]. Furthermore, we and others have pre-
viously shown that the synthetic glucocorticoid Dexamethasone
(Dex) inhibits PGE2 production by inhibiting mPGES-1
expression [24,32,36].
The cytosolic PGE synthase cPGES is considered constitu-
tively expressed and functionally coupled with COX-1,
supported by evidence from various cell types [18,20,37,38].
The second microsomal PGE synthase isoform, mPGES-2, has
not been extensively studied and the expression and inducibility
seem to vary between different cell types, in response to in-
flammatory stimuli [12,20,39,40]. A study by Kubota et al. on
mPGES-1 knockout mice indicated that mPGES-2 may play a
compensatory role in inflammatory-induced PGE2 production
in myometrium, substituting for mPGES-1 [41]. Conversely,
mPGES-2 expression was not increased by LPS treatment in
microglia derived from mPGES-1 knockout mice in a study by
Ikeda-Matsuo et al. [32].
The PGE synthases are emerging as possible target enzymes
for therapeutic management of inflammatory diseases, due to
the side-effects of the selective COX-2 inhibitors, as well as the
adverse effects of chronic use of the traditional non-selective
non-steroid anti-inflammatory drugs [42–44]. However, the
regulatory interplay between PGE synthase isoforms has not
been thoroughly investigated. The expression of all three iso-
forms has recently been reported in gastritis and gastric ulcer
tissue [20], and there are also indications that PGE synthases
may be involved in colorectal tumor development as well as in
lung and breast cancer [25,30,45,46]. The exploration of PGE
synthases is ongoing, and to our knowledge, the expression and
regulation of all three PGE synthases has not previously been
investigated, either in periodontal tissue or in gingiva.
In this study, we utilized small interfering RNA (siRNA)
technology, aiming to elucidate the impact of knocking down
mPGES-1 expression on the expression of mPGES-2 and
cPGES as well as on prostaglandin production. The expression
of PGE synthases and production of PGE2 and PGF2α was
investigated in response to inflammatory mediators IL-1β or
TNFα in the presence or absence of siRNA targeting mPGES-1.
In addition, we have studied the effect of Dex as well as MK-
886 on the cytokine-induced expression of mPGES-1 as well as
on the expression of PGE synthase isoforms mPGES-2 and
cPGES. In the present study we demonstrate, for the first time,
that siRNA knocked down mPGES-1 expression, and that
neither mPGES-2 nor cPGES substitute for mPGES-1 when this
isoenzyme is knocked down by siRNA or inhibited by Dex orMK-886. Furthermore, PGE2 levels were unchanged when
mPGES-1 was knocked down by siRNA, whereas PGF2α levels
were elevated, indicating a compensatory pathway through
which PGE2 may be synthesized via the increased PGF2α.
2. Materials and methods
2.1. Cell cultures of gingival fibroblasts
Human gingival fibroblasts were established from gingival biopsies
obtained from 5 healthy patients, 6 to 12 years of age with no clinical signs
of periodontal disease. The protocol, including the collection of gingival biopsy,
was approved by the Ethical Committee at the Huddinge University Hospital.
Minced pieces of gingival tissue were explanted to 25 cm2 Falcon tissue culture
flasks containing 5 ml of Dulbecco's Modified Eagle Medium (DMEM)
supplemented with penicillin (50 units/ml), streptomycin (50 μg/ml) and 5%
fetal calf serum (FCS, Invitrogen Life Technologies, Scotland, UK). Gingival
fibroblasts were obtained by trypsinization of the primary outgrowth of cells.
The cells were grown at 37 °C with 5% CO2 and routinely passaged using
0.025% trypsin in phosphate-buffered saline (PBS) containing 0.02% EDTA.
Gingival fibroblasts were seeded in 60-mm Petri dishes in DMEM
supplemented with 5% FCS and cultured for 24 h at 37 °C. The cell layers
were then rinsed with serum-free DMEM followed by the addition of 2.0 ml
DMEM containing one of the inflammatory mediators IL-1β and TNFα in the
absence or presence of Dexamethasone (Dex; Sigma-Aldrich, St. Louis, MO,
USA) or MK-886 (Cayman Chemical Company, Ann Arbor, MI, USA). Control
cells were treated with culture medium only. After an incubation period, culture
medium was removed and stored at −20 °C for subsequent PGE2 determination.
The cell monolayer was washed twice with ice-cold PBS and either frozen
immediately in liquid nitrogen and then stored at −70 °C for subsequent
isolation of total RNA, or immediately lysed for protein isolation.
2.2. Knock-down of mPGES-1 using small interfering RNA (siRNA)
Gingival fibroblasts were seeded in 6-well cell culture plates or 6-cm Petri
dishes in DMEM supplemented with 5% FCS and cultured for 24 h at 37 °C.
The cell layers were then rinsed with serum-free DMEM followed by the
addition of DMEM containing HiPerFect transfection reagent (3 μl/100 μl,
Qiagen) and siRNA against mPGES-1 (5–10 nM Hs_PTGES_1 HP Genome-
Wide siRNA, sense: r(GGG UGA CCA GCC ACU CAA A)dTdT, Qiagen).
After 18 h of incubation, the medium was changed to DMEM supplemented
with 5% FCS, and the cells were allowed to recover for 6 h before stimulation
with serum free medium with or without TNFα (20 ng/ml) or IL-1β (0.5 ng/ml)
for 18 h. After stimulation, culture medium was removed and stored at −20 °C
for subsequent PGE2 determination, and the cells were harvested for flow
cytometric, Western blot or activity analysis.
2.3. Flow cytometry
Gingival fibroblasts were seeded in 6-well plates and grown as described
above. After treatment, the fibroblasts were collected by trypsinization and
washed three times with PBS. Thereafter, the cells were fixed in 2%
paraformaldehyde for 15 min at room temperature (RT) and washed with PBS
prior to permeabilization with PBS containing 0.1% Saponin (SAP buffer)
(15 min, RT). After washing with SAP buffer, the cells were incubated with
primary antibodies for mPGES-1 (monoclonal mouse, Cayman) mPGES-2
(polyclonal rabbit, Cayman), cPGES (polyclonal rabbit, Cayman) or COX-2
(monoclonal mouse, Cayman) in the dark for 40 min (RT). All antibodies were
titrated in preliminary experiments. After washing with SAP-buffer, the cells
were incubated with a secondary goat anti-mouse Fluorescein Isothiocyanate
(FITC) labeled antibody (DakoCytomation, Glosrup, Denmark) or sheep anti-
rabbit Phycoerythrin (PE) labeled antibody (Serotec, Oxford, UK) for 40 min at
4 °C in the dark. After washing with SAP-buffer, the fibroblasts were
resuspended in PBS and analyzed in a FACSCalibur™ flow cytometer using
CellQuest software (Becton & Dickinson, San Jose, CA, USA). Between 10000
and 20000 events per test were acquired. To analyze the expression of mPGES-1,
1591T. Båge et al. / Biochimica et Biophysica Acta 1773 (2007) 1589–1598mPGES-2, cPGES and COX-2, a gated area was selectively determined for the
cells using forward vs. side scatter parameters. The results obtained are shown as
histograms of cell counts, drawn using the program R, together with the package
rflowcyt [47,48].
2.4. Measurement of mPGES-1 activity
Gingival fibroblasts were seeded in 6-cm Petri dishes in DMEM
supplemented with 5% FCS and cultured for 24 h at 37 °C. The cell layers
were then rinsed with serum-free DMEM followed by treatment with DMEM
containing TNFα (20 ng/ml) or IL-1β (0.5 ng/ml) (24 h, 37 °C) or with siRNA
and TNFα as described in Section 2.2. After incubation, the cells were collected
by trypsinization, followed by centrifugation and resuspension of the pellet in
250 μl 10 mMTris–HCl pH 8.0. The samples were frozen in −20 °C and thawed
in three cycles. Samples were sonicated to disrupt the cells, followed by
centrifugation for 10 min (4 °C, 3000 rpm). The supernatant was collected and
used in the activity assay, as previously described [49,50]. In the activity assay,
equal amounts of protein (20–40 μg) from each sample within the same
experiment was incubated with 1 μg PGH2 (Cayman) in 0.5 M Tris–HCl pH 8.0
supplemented with 0.5 mMglutathione (Sigma-Aldrich) in a total reaction volume
of 200 μl. The reaction was allowed to proceed for 60 s at RT, and was thereafter
terminated by addition of 100 mM FeCl2 (Sigma-Aldrich). Following centrifuga-
tion, the supernatants were collected and frozen (−20 °C) for subsequent PGE2
measurement. The mPGES-1 activity is expressed as nmol PGE2/min/mg protein.
The activity measured in this assay includes the glutathione-dependent activity of
the induced mPGES-1 as well as the constitutive isoform cPGES.
2.5. RNA isolation and reverse transcription polymerase chain
reaction (RT-PCR)
Gingival fibroblasts were seeded in 6-cm Petri dishes and grown as
described above. Total RNA was isolated from gingival fibroblasts using the
commercially available RNeasy kit (Qiagen Inc., CA, USA) and quantified
spectrophotometrically at 260/280 nm. To obtain first strand cDNA, 1.0 μg of
total RNAwas reverse transcribed using Superscript II in a total volume of 20 μl.
The obtained cDNA (2.0–4.0 μl) was used as a template for PCR amplification
as described in the protocol of Superscript II (Invitrogen) using AmpliTaq Gold
DNA polymerase (Applied Biosystems, CA, USA) in a final reaction volume of
50 μl. The primers used for PCR amplification were: 5′-CCA AGT GAG GCT
GCG GAA GAA-3′ and 3′-GCT TCC CAG AGG ATC TGC AGA-5′ for
mPGES-1 (GenBank accession number NM_004878); 5′-CCT CAT CAG CAA
GCG ACT CAA-3′ and 3′-GTG GAC AAG GGG CAG AAT GAT-5′ for
mPGES-2 (GenBank accession number NM_025072); 5′-GGG TGG TGATGA
GGATGTAGA-3′ and 3′-AGG AGA CTTAGG TGA GAT GTT-5′ for cPGES
(GenBank accession number NM_006601); 5′-TTC AAATGAGAT TGTGGG
AAA ATT GCT-3′ and 3′-TTC TAT GAG TCC GTC TCT ACT AGA-5′ for
COX-2 (GenBank accession number NM_000963). The samples were amplified
(Gene Amp PCR 9600; Perkin Elmer, MA, USA) by an initial denaturation for
10 min at 94 °C, followed by a denaturation step at 94 °C for 45 sec; annealing
step at 58 °C for 45 sec and an extension step at 72 °C for 45 sec for 30 cycles
(35 cycles for mPGES-2) and a final extension for 10 min at 72 °C. As a control,
GAPDH was also amplified, using primers supplied from R&D Systems
(Minneapolis, MN, USA), according to the recommendations of the
manufacturer. Of each PCR reaction product, 10 μl was analyzed on a 2%
agarose gel with ethidium bromide (E-gel, Invitrogen), together with 1 kb DNA-
ladder standard (Invitrogen). For each experiment, PCR amplifications without
cDNA were performed as negative controls.
2.6. Western blot analysis
Fibroblasts were seeded in 6-cm Petri dishes and grown as described above.
To isolate the proteins of the cell monolayer, the fibroblasts were resuspended in
PBS and centrifuged. The pellet was then resuspended in lysis buffer (10 mM
HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT and
protease inhibitors: 1 mM PMSF, pepstatin, aprotinin and leupeptin at 1 μg/ml).
The cell lysates were centrifuged and the protein concentration was determined
using the Bradford method (Protein Assay; Bio-Rad Laboratories, Hercules,CA, USA) using bovine serum albumin (Sigma-Aldrich) as standard. Equal
amounts of the obtained protein were separated by electrophoresis on a 10%
sodium dodecyl sulfate-polyacrylamide gel and transferred to a nitrocellulose
membrane (Bio-Rad). The membrane was then blocked in blocking buffer (tris
buffered saline, TBS, pH 8.0 with 5% defatted dry milk; Bio-Rad) for 1 h and
incubated at 4 °C over night in blocking solution with primary antibody diluted
1:200 for mPGES-1 (monoclonal mouse IgG, Cayman), 1:250 for mPGES-2
(polyclonal rabbit IgG, Cayman), 1:150 for cPGES (polyclonal rabbit IgG,
Cayman) and 1:1000 for COX-2 (monoclonal mouse IgG, Cayman).
Subsequently, the membranes were washed in TBST (TBS with 0.1% Tween
20) and incubated for 1 h in RT with horseradish peroxidase-conjugated
secondary antibody, diluted in blocking buffer (1:1000 goat anti-mouse or
1:2000 swine anti-rabbit; Dako Corporation, A/S, Denmark). Finally, the
membranes were washed in TBST, developed using enhanced chemilumines-
cence (ECL) (Amersham Biosciences, Bucks, UK) and exposed to hyperfilm-
ECL (Amersham Biosciences).
2.7. Prostaglandin E2 and prostaglandin F2α determination
The amount of PGE2 in the medium was determined using Luminex
technology on a Bio-plex Suspension Array System (Bio-Rad) using a
commercially available luminex enzyme immunoassay (EIA) kit (Cayman).
The amount of PGF2α in the mediumwas determined using an EIA kit (Cayman).
2.8. Analysis of 3H-arachidonic acid (3H-AA) release
Gingival fibroblasts were seeded in 24-well plates in DMEM supplemented
with 5% FCS and cultured for 24 h at 37 °C. The cells were then transfected with
mPGES-1 siRNA (10 nM) and allowed to recover, as previously described in
Section 2.2. Following transfection and recovery, cells were washed with serum-
free medium followed by addition of serum-free medium containing 1 μCi/ml
3H-AA. After 20 h of incubation, the cells were washed twice, and incubated
with or without the cytokine TNFα (20 ng/ml) for an additional 24 h. The culture
medium was removed and analyzed for 3H using a scintillation counter. To
obtain the total activity, cell layers were lysed in lysis buffer (10 mMHEPES pH
7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT) and analyzed
using a scintillation counter. The results are presented as 3H release divided by
total 3H activity (medium and cells), relative to control cells. The activity of 3H
represents free 3H-AA as well as 3H-labeled metabolites.
2.9. Statistics
All experiments were repeated a minimum of three times. Student's t test
(two-tailed) was used for quantitative comparisons and Pb0.05 was considered
statistically significant.
3. Results
3.1. Effect of TNFα and IL-1β on mPGES-1, mPGES-2, cPGES
and COX-2 expression and on mPGES-1 activity
We have previously shown that mPGES-1 expression is
increased by the inflammatory cytokines IL-1β and TNFα in
gingival fibroblasts [24]. In this study, the effect of these
cytokines on the expression of all three PGE synthases,
mPGES-1, mPGES-2 and cPGES, in relation to COX-2
expression, was investigated. As shown in Fig. 1A, the protein
expression of mPGES-1 was induced by IL-1β (0.1–0.5 ng/ml)
as well as TNFα (5–20 ng/ml) in a dose-dependent manner in
24 h cultures. In unstimulated control cells, there was low or no
protein expression of mPGES-1. The other two isoforms of PGE
synthase, mPGES-2 and cPGES, were found to be expressed in
unstimulated control fibroblasts. However, mPGES-2 and cPGES
protein expression, in contrast to mPGES-1, was not increased in
Fig. 1. The cytokines TNFα and IL-1β increase mPGES-1 and COX-2
expression, but not the expression of mPGES-2 or cPGES. (A) Gingival
fibroblasts were stimulated with TNFα (5-20 ng/ml) or IL-1β (0.1–0.5 ng/ml)
for 24 h, and protein expression of PGE synthases and COX-2 was detected by
Western blot. Control cells were treated with culture medium only. (B) Cells
were stimulated with TNFα (20 ng/ml) or IL-1β (0.5 ng/ml) for 6 h, and mRNA
expression was detected by semi-quantitative RT-PCR. Results shown are
representative from at least three independent experiments.
Fig. 2. The cytokines increase the expression and activity of mPGES-1 but not
the expression of mPGES-2 or cPGES. Gingival fibroblasts were stimulated
with TNFα (20 ng/ml) or IL-1β (0.5 ng/ml) for 24 h. Control cells were treated
with culture medium only. (A) Cellular protein expression of mPGES-1 detected
using flow cytometry. (B) Cellular protein expression of mPGES-2 and cPGES
detected using flow cytometry. (C) Gingival fibroblasts were stimulated with
TNFα (20 ng/ml) for 24 h. Cell lysates were used in an in vitro reaction
measuring the activity of mPGES-1 converting PGH2 to PGE2, as described in
Section 2. The results were expressed as nmol PGE2/min/mg protein. Asterisk
indicates a significant difference from control cells. Results shown are
representative from at least three independent experiments.
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(Fig. 1A). Similar to mPGES-1, IL-1β and TNFα (24 h cultures)
dose-dependently increased the expression of COX-2, the enzyme
upstream of PGE synthases in PGE2 biosynthesis (Fig. 1A). RT-
PCR analysis showed that the mRNA expression of mPGES-1
was induced by IL-1β (0.5 ng/ml) and TNFα (20 ng/ml) in 6 h
cultures (Fig. 1B). The two PGE synthase isoformsmPGES-2 and
cPGES were constitutively expressed at mRNA level, but their
expression was not stimulated by the inflammatory cytokines
TNFα and IL-1β (Fig. 1B). In accordance with previous results
[51,52], IL-1β and TNFα (6 h) increased themRNAexpression of
COX-2 (Fig. 1B). Moreover, flow cytometric analysis demon-
strated an increase in mPGES-1 protein expression in cells treated
with IL-1β (0.5 ng/ml) as well as TNFα (20 n/ml) at 24 h
(Fig. 2A), in concordancewithWestern blot results. As revealed in
the flow cytometry histograms in Fig. 2B, mPGES-2 and cPGES
expression was neither affected by IL-1β nor TNFα treatment.
Moreover, the activity of mPGES-1 was analyzed using an in
vitro activity assay. As demonstrated in Fig. 2C, the mPGES-1
activity was increased in cell extracts from fibroblasts treated with
the inflammatory cytokine TNFα, compared to control cells.
Similar results were seen in cells stimulated with IL-1β (data not
shown). Furthermore, the stimulatory effect of TNFα and IL-1β
on the expression of mPGES-1 and COX-2 was accompanied by
dose-dependent stimulation in the production of the end product
PGE2, with IL-1β being the most potent in this regard (Fig. 3).
3.2. RNA interference targeting mPGES-1
To elucidate the role of mPGES-1 in inflammatory-induced
PGE2 production, we used siRNA knock-down technique,followed by Western blot, flow cytometry and PGE2 production
analysis [53,54]. Fibroblasts were transfected with siRNA
targeting mPGES-1, followed by stimulation with TNFα
(20 ng/ml) or IL-1β (0.5 ng/ml). In cells transfected with
mPGES-1 siRNA (10 nM), the stimulatory effect of TNFα on
mPGES-1 expression was reduced (39–77%), compared to cells
pre-treated with transfection reagent only (mock transfection),
as demonstrated by flow cytometric analysis in Fig. 4A. In
accordance with results obtained with TNFα, also the IL-1β-
induced mPGES-1 expression was decreased (54–79%) after
treatment with mPGES-1 siRNA (10 nM). Furthermore, the
protein expression analyzed by Western blot showed that
siRNA (5 and 10 nM) dose-dependently decreased TNFα-
induced mPGES-1 expression in 24 h cultures (Fig. 4B).
Similarly, siRNA (10 nM) also reduced the IL-1β-induced
mPGES-1 protein expression (Fig. 4B). Moreover, analysis of
mPGES-1 activity showed that siRNA (10 nM) knockdown of
mPGES-1 reduced the TNFα-stimulated (20 ng/ml) mPGES-1
activity to control levels, as demonstrated in Fig. 4C.
Fig. 4. siRNA silencing reduces mPGES-1 protein expression and activity.
Gingival fibroblasts were treated with siRNA (5–10 nM) targeting mPGES-1,
followed by stimulation of cells with TNFα (20 ng/ml) or IL-1β (0.5 ng/ml).
Control cells were treated with transfection reagent only (mock transfection).
(A) Cellular protein expression of mPGES-1 in cells treated with siRNA
(10 nM), as analyzed by flow cytometry. (B) Expression of mPGES-1 as
analyzed by Western blot. (C) mPGES-1 activity was analyzed in cell extracts,
as described in Section 2. The results were expressed as nmol PGE2/min/mg
protein. Asterisk indicates a significant difference (Pb0.05). Results shown are
representative from at least three independent experiments.
Fig. 3. TNFα and IL-1β dose-dependently stimulate PGE2 production in
gingival fibroblasts. Gingival fibroblasts were stimulated with TNFα (5–20 ng/
ml) or IL-1β (0.1–0.5 ng/ml) for 24 h, and the release of PGE2 into the culture
medium was analyzed by enzyme immunoassay. Control cells were treated with
culture medium only. Samples were analyzed in triplicates and the results are
expressed as mean with standard deviation. Asterisks indicate a significant
difference from control cells (Pb0.05). Results shown are representative from at
least three independent experiments.
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expression
To investigatewhethermPGES-2 and/or cPGESmay substitute
for mPGES-1 in inflammatory-induced PGE2 production, we
studied the expression of the two PGE synthase isoformsmPGES-
2 and cPGES in cells treated withmPGES-1 siRNA in the absence
or presence of cytokines. Flow cytometric analysis showed that
neither mPGES-2 nor cPGES protein expression was affected
by mPGES-1 siRNA treatment (10 nM), as demonstrated in
Fig. 5A. Similar to flow cytometric analysis,Western blot analysis
revealed a lack of inhibitory effect of mPGES-1 siRNA (5 and
10 nM) on mPGES-2 and cPGES protein expression (Fig. 5B).
3.4. Effect of mPGES-1 siRNA on COX-2 expression and PGE2
production
We also investigated the effect of mPGES-1 siRNA on the
upstream enzyme COX-2 as well as on PGE2 production. The
results demonstrated that siRNA targeting mPGES-1 did not
markedly affect the cytokine-stimulated protein expression of
COX-2, as shown in Fig. 6. Moreover, mPGES-1 siRNA did not
affect the production of PGE2 stimulated by TNFα (Fig. 7A) or
IL-1β (data not shown).
3.5. Effect of mPGES-1 siRNA on 3H-AA-release and PGF2α
production
To gain some insight into the mechanisms behind the un-
changed PGE2 levels in mPGES-1 knock-down cells, we studied
the prostaglandin pathway upstream and downstream of the
enzyme mPGES-1. Upstream, we investigated the release of
arachidonic acid and downstream the production of PGF2α, which
can be synthesized both from PGE2 and directly from PGH2.
Analysis of 3H-AA showed that the inflammatory cytokine TNFα
(20 ng/ml) increased the release of 3H-AA in gingival fibroblasts.
Furthermore, treatment of the cells with mPGES-1 siRNA did not
affect 3H-AA release increased by TNFα (Fig. 7C).We also investigated the effect of mPGES-1 siRNA on the
production of the prostaglandin PGF2α. The results showed that
TNFα (20 ng/ml) increased the production of PGF2α in gingival
fibroblasts. Moreover, in cells transfected with siRNA targeting
mPGES-1, the TNFα-increased production of PGF2α was
upregulated compared to cells treated with mock transfection
and TNFα (Fig. 7B).
3.6. Effect of MK-886 on the expression of PGE synthases and
PGE2 production
The indole FLAP inhibitor MK-886 has been shown to
inhibit mPGES-1 activity in chondrocytes and in vitro protein
assays [34,35]. However, to our knowledge there is no
information regarding the effect of MK-886 on the expression
of PGE synthases. In this study, we investigated the effect of
Fig. 7. Effect of mPGES-1 siRNA on PGE2 production, PGF2α production and
3H-AA release. Gingival fibroblasts were treated with siRNA (5–10 nM)
targeting mPGES-1, followed by stimulation of cells with TNFα (20 ng/ml).
Control cells were treated with transfection reagent only (mock transfection).
(A) Release of PGE2 into the culture medium was analyzed by enzyme
immunoassay. No significant difference was found after siRNA transfection as
Fig. 5. siRNA targeting mPGES-1 does not affect mPGES-2 or cPGES
expression. (A) Gingival fibroblasts were treated with siRNA (10 nM) targeting
mPGES-1, followed by stimulation of cells with TNFα (20 ng/ml). Control cells
were treated with transfection reagent only (mock transfection). Cellular protein
expression of mPGES-2 and cPGES was detected using flow cytometry.
(B) Gingival fibroblasts were treated with siRNA (10 nM) targeting mPGES-1,
followed by stimulation of cells with TNFα (20 ng/ml) or IL-1β (0.5 ng/ml).
Protein expression of mPGES-2 and cPGES was analyzed by Western blot.
Results shown are representative from at least three independent experiments.
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relation to COX-2. Treatment of the cells with MK-886 (2–
8 μM) reduced the IL-1β-induced mPGES-1 expression as
demonstrated by Western blot analyses (Fig. 8A). On the
contrary, the expression of the isoenzymes mPGES-2 and
cPGES was not markedly affected by MK-886 (Fig. 8A). The
reduction of mPGES-1 expression by MK-886, as well as theFig. 6. mPGES-1 siRNA does not affect COX-2 expression. Gingival fibroblasts
were treated with siRNA (10 nM) targeting mPGES-1, followed by stimulation
of cells with TNFα (20 ng/ml) or IL-1β (0.5 ng/ml). Control cells were treated
with transfection reagent only (mock transfection). Cellular protein expression
of COX-2 was analyzed using flow cytometry. Results shown are representative
from at least three independent experiments.
compared to corresponding cells treated with TNFα only. Samples were
analyzed in triplicates and the results are expressed as mean with standard
deviation. (B) Release of PGF2α into the culture medium was analyzed by
enzyme immunoassay. Samples were analyzed in triplicates and the results are
expressed as relative to control cells, with standard deviation. Asterisk indicates
a significant difference from corresponding cells treated with TNFα only
(Pb0.05). (C) Release of 3H-AA into the medium was measured by scintillation
counter. Samples were analyzed in triplicates and the results are divided by total
3H activity in the cells and medium, and expressed as relative to control cells,
with standard deviation. No significant difference (N.S.) was found after siRNA
transfection as compared to corresponding cells treated with TNFα only.
Asterisks indicate a significant difference (Pb0.05). Results shown are
representative from at least three independent experiments.lack of effect on mPGES-2 and cPGES, was also seen in cells
stimulated with the cytokine TNFα, as demonstrated in Fig. 8B.
The inhibitor MK-886 did not affect the expression of the
upstream enzyme COX-2 at the lower doses (2–4 μM), whereas
COX-2 expression was increased at a higher dose of MK-886
(8 μM), both alone and in combination with IL-1β or TNFα
(Fig. 8A and B). Moreover, as shown in Fig. 8C, treatment of
gingival fibroblasts with MK-886 (2–4 μM) did not signifi-
cantly affect PGE2 production. However, MK-886 at a con-
centration of 8 μM, in accordance with COX-2 expression,
Fig. 8. Effect of MK-886 on mPGES-1, mPGES-2, cPGES and COX-2
expression as well as PGE2 production. (A) Gingival fibroblasts were treated
with MK-886 (2–8 μM) in the presence or absence of IL-1β (0.5 ng/ml) for
24 h. Control cells were treated with culture medium only. Protein expression of
PGE synthases and COX-2 was detected using Western blot. (B) Gingival
fibroblasts were treated with MK-886 (2–8 μM) in the presence or absence of
TNFα (20 ng/ml) for 24 h. Protein expression of PGE synthases and COX-2 was
detected using Western blot. (C) Gingival fibroblasts were treated with MK-886
(2–4 μM) in the presence or absence of TNFα (20 ng/ml) or IL-1β (0.5 ng/ml)
for 24 h. The release of PGE2 into the culture medium was analyzed by enzyme
immunoassay. Samples were analyzed in triplicates and the results are expressed
as mean with standard deviation. No significant difference was found after
treatment with MK-886, compared to cells stimulated with cytokines only or
control cells. Results shown are representative from at least three independent
experiments.
Fig. 9. Dex decreases TNFα-induced mPGES-1 and COX-2 expression, but not
mPGES-2 and cPGES expression. Gingival fibroblasts were treated with the
glucocorticoid Dex (1.0 μM) in the presence or absence of TNFα (20 ng/ml) or
IL-1β (0.5 ng/ml) for 24 h. Control cells were treated with culture medium only.
(A) Cellular protein expression of mPGES-1 as detected using flow cytometry.
(B) Protein expression of PGE synthases and COX-2 as analyzed by Western
blot. Results shown are representative from at least three independent
experiments.
Fig. 10. Dex reduces TNFα-induced PGE2 production. Gingival fibroblasts
were treated with the glucocorticoid Dex (1.0 μM) in the presence or absence of
TNFα (20 ng/ml) or IL-1β (0.5 ng/ml) for 24 h. Control cells were treated with
culture medium only. The release of PGE2 into the culture mediumwas analyzed
by enzyme immunoassay. Samples were analyzed in triplicates and the results
are expressed as mean with standard deviation. Asterisks indicate a significant
difference from cells treated with cytokine only (Pb0.05). Results shown are
representative from at least three independent experiments.
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bination with IL-1β or TNFα (data not shown).
3.7. Effect of Dexamethasone (Dex) on the expression of PGE
synthases and PGE2 production
We have previously demonstrated that the anti-inflammatory
steroid Dex inhibits mPGES-1 expression induced by inflam-
matory mediators TNFα or IL-1β in gingival fibroblasts [24].
Flow cytometric analysis showed that treatment of fibroblasts
with Dex (1 μM) in the presence of TNFα or IL-1β reduced
mPGES-1 protein expression induced by cytokines (Fig. 9A).
The effect of Dex on the protein expression of PGE synthases
was also shown by Western blot analysis, demonstrating thatDex reduced mPGES-1 without affecting the expression of
mPGES-2 or cPGES (Fig. 9B). The protein expression of COX-
2, on the other hand, was reduced by Dex in accordance with
mPGES-1, as shown in Fig. 9B. Moreover, Dex also inhibited
1596 T. Båge et al. / Biochimica et Biophysica Acta 1773 (2007) 1589–1598PGE2 production in the cells stimulated by the inflammatory
cytokines IL-1β or TNFα, as demonstrated in Fig. 10.
4. Discussion
We have previously shown that the expression of mPGES-1
is induced by the inflammatory mediators TNFα and IL-1β,
with a concomitant increase in PGE2 production [28]. In this
study, we investigated the expression and regulation of all three
PGE synthase isoenzymes mPGES-1, mPGES-2 and cPGES in
gingival fibroblasts. The results show that neither mPGES-2 nor
cPGES, in contrast to mPGES-1, was increased by the inflam-
matory cytokines TNFα and IL-1β, indicating a lack of partici-
pation of these isoenzymes in inflammatory-induced PGE2
production. Furthermore, we demonstrate that the cytokine-
induced mPGES-1 protein expression and activity are decreased
upon transfection with mPGES-1 siRNA. In addition, we also
show that neither siRNA silencing nor inhibition of mPGES-1
expression is compensated by an upregulation of mPGES-2 or
cPGES expression.
Our findings that cPGES is not upregulated by cytokines
are consistent with results from other cell types including or-
bital fibroblasts, chondrocytes and human gastric fibroblasts
[20,35,36]. Concerning mPGES-2 expression, our results are in
agreement with findings obtained in cardiac fibroblasts, gastric
fibroblasts and renal mesangial cells, demonstrating no increase
ofmPGES-2 expression upon treatment with IL-1β [20,22,55]. In
contrast, an induction of mPGES-2 has been shown in microglial
cells upon stimulation with LPS, suggesting a cell-specific
expression of mPGES-2 in response to pro-inflammatory stimuli
[56]. It has been suggested that in the event of reduced mPGES-1
expression, there might be a compensatory increase of the
expression of mPGES-2 and/or cPGES. We investigated this
hypothesis using siRNA knock-down of mPGES-1. The results
showed no upregulation ofmPGES-2 or cPGES following knock-
down of mPGES-1 by specific siRNA. These results are in line
with Ikeda-Matsuo et al. showing no increase in mPGES-2
expression in rat microglial cells when using an antisense oligo-
nucleotide targeting mPGES-1 [32]. In contrast, in myometrium
of mPGES-1 knockout mice an increase of mPGES-2 expression
in response to LPS treatment has been reported [41]. Thus, the
results suggest that the expression ofmPGES-2may vary between
cell types, and in gingival fibroblasts this isoenzyme does not
seem to have any compensatory role in response to inflammatory
mediators, when knocking down mPGES-1 by siRNA silencing.
To further explore the regulation of the isoenzymes mPGES-
2 and cPGES, the expression of these enzymes was studied in
the presence of the mPGES-1 inhibitor MK-886. The indole
MK-886 is a potent inhibitor of the leukotriene B4 pathway, but
has also been shown to have an inhibitory effect on mPGES-1
activity [35,57,58]. We here demonstrate that the nonselective
mPGES-1 inhibitor MK-886 reduced mPGES-1 protein ex-
pression in both TNFα- and IL-1β-stimulated cells. In accor-
dance with our mPGES-1 siRNA results, the PGE synthase
isoenzymes mPGES-2 and cPGES were not affected by MK-
886, supporting the proposed lack of compensatory role for
these isoenzymes in the event of mPGES-1 inhibition. Theinhibitory effect of MK-886 on mPGES-1 is in line with pre-
vious studies demonstrating an inhibition of mPGES-1 activity
by MK-886 in chondrocytes and gastric fibroblasts as well as in
vitro enzymatic reactions [20,34,35,59].
Based on our findings that the anti-inflammatory glucocor-
ticoid Dex inhibits cytokine-induced mPGES-1 expression [24],
we further studied the effect of Dex also on mPGES-2 and
cPGES expression. In contrast to its effect on mPGES-1, Dex
did not inhibit the expression of mPGES-2 and cPGES, further
indicating a lack of involvement in inflammatory conditions.
The expression of cPGES has also been shown to be unaffected
by Dex in macrophages and amnion fibroblasts [25,60].
In the current study, we also report that siRNA targeting
mPGES-1 did not reduce the PGE2 production upregulated by
cytokines, although it down-regulated mPGES-1 protein ex-
pression and activity. To explore the mechanism(s) behind this
finding, experiments involving PLA2 activity and PGF2α pro-
duction were performed. The results showed that PLA2 activity,
measured as 3H-AA release, was not affected by mPGES-1
siRNA in TNFα-stimulated cells compared to corresponding
cells treated with TNFα only. This finding may indicate that the
lack of PGE2 reduction, in response to mPGES-1 siRNA, is not
due to upregulation of AA release in gingival fibroblasts.
To further explore the sustained PGE2 levels in response to
mPGES-1 siRNA, we also analyzed the production of another
prostaglandin, PGF2α, which is known to be synthesized via
different pathways, including from PGE2 and directly from the
COX-2 product PGH2 [14]. Interestingly, we observed that
siRNA knockdown of mPGES-1 resulted in an increased pro-
duction of PGF2α in cytokine-stimulated cells, suggesting a
compensatory pathway by which the production of PGE2 oc-
curs. It is possible that when mPGES-1 is knocked down by
siRNA, the COX-2 derived PGH2 may be shunted towards
PGF2α, which in turn can be converted to PGE2 by PGE 9-
ketoreductase [14], and thereby contribute to PGE2 synthesis.
However, further studies are needed to clarify the prostaglandin
synthesis when mPGES-1 is down-regulated.
Another possible explanation for the lack of reduction of
PGE2, in the presence of mPGES-1 siRNA, may be that the
conversion of PGH2 to PGE2 is not the rate-limiting step of PGE2
biosynthesis in gingival fibroblasts in the current setting. Instead,
COX-2 expression seems more closely linked to PGE2 pro-
duction, which indicates the COX-2 enzyme as the rate-limiting
enzyme; a notion that has been previously suggested in several
publications [61–63]. Similar to our PGE2 results, the cytokine-
induced expression of COX-2 also remained unaffected when
knocking down mPGES-1. This is in accordance with our
previous results demonstrating a tight correlation betweenCOX-2
expression and PGE2 production in gingival fibroblasts stimulat-
ed with cytokines [28]. Likewise, the production of PGE2 as well
as the expression of COX-2 was unaffected by MK-886 at lower
doses (2–4 μM), whereas both COX-2 expression and PGE2
production increased at higher concentrations. Similar results
regarding the effect of MK-886 on PGE2 production have been
reported in joint exudates [64] and in human tendon fibroblasts
[65]. The observed increase of PGE2 production after treatment
with 8 μM MK-886 is in line with, and might be due to, the
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effect of MK-886 on PGE2 production may be due to shunting of
PGH2 to the prostaglandin pathway, since MK-886 is a
leukotriene pathway inhibitor. Altogether, the lack of inhibitory
effect ofmPGES-1 siRNA andMK-886 on PGE2 productionmay
indicate that neither siRNA-mediated knockdown nor MK-886
may serve as a potential inhibitor of mPGES-1 resulting in in-
hibition of PGE2 production. Thus, additional studies are ongoing
to study the effect of other, more specific, mPGES-1 inhibitors
which also decrease the synthesis of the pro-inflammatory
mediator PGE2, by targeting the enzyme at the activity level.
In summary, this study shows, for the first time, that mPGES-1
expression was down-regulated by specific mPGES-1 siRNA.
The PGE synthase isoenzymes mPGES-2 and cPGES were unaf-
fected by the knockdown and inhibition of mPGES-1 expression,
refuting a possible compensatory role for these two isoenzymes in
inflammatory-induced PGE2 production in gingival fibroblasts.
Transfection with mPGES-1 specific siRNA did not decrease the
production of PGE2, although it down-regulated mPGES-1
protein expression and activity. In contrast, PGF2α production
was increased by mPGES-1 siRNA, suggesting a compensatory
mechanism by which PGE2 may be synthesized when mPGES-1
is knocked down.
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